Releaf
Graham Woodward RNMH FCMI currently serves as Chief Operating Officer at Releaf since January 2024. Previously, Graham held multiple roles at Leva Clinic, including Quality Assurance Director and Director of Clinical Services from January 2022 to January 2024. At MyAccess Clinics, Graham worked as Clinical Director from February 2019 to January 2022, overseeing site identification, CQC registration, and compliance with clinical standards while developing the wider team and patient recruitment strategies. Prior experience includes serving as a Medical Science Liaison at Indivior from January 2013 to January 2019. Graham earned a degree from Middlesex University between 2002 and 2006.
This person is not in any teams
Releaf
1 followers
Releaf, founded in 2022, is a healthcare company dedicated to transforming patient access to Cannabis Based Products for Medical use (CBPMs) in the UK. Despite the legalisation of medical cannabis in 2019, its uptake has been limited. An estimated 1.8 million people in the UK rely on illicit street cannabis for medical purposes, while over 20 million adults could benefit from CBPMs but are unaware of their options. Currently, only around 30,000 people in the UK have an active CBPM prescription. The primary obstacles to broader adoption are the complexity of the prescribing process and a lack of awareness among medical professionals and potential patients. Releaf has made significant investments in developing a HealthTech platform to streamline access to CBPMs for patients with various health conditions. The platform was launched in February 2024, eliminating previous barriers and bringing about fundamental changes in the UK's CBPM sector. Our Leadership Team has a proven track record in navigating complex, regulated markets. Through substantial investments in time, money, and expertise, we have developed Releaf's HealthTech operating platform. This platform simplifies the intricate and makes the opaque transparent, ensuring a seamless, single online session for patients to access CBPMs for their relevant conditions. Press enquiries: Press@releaf.co.uk